Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result (PCA3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01024959
Recruitment Status : Completed
First Posted : December 3, 2009
Results First Posted : November 7, 2012
Last Update Posted : November 12, 2012
Sponsor:
Information provided by (Responsible Party):
Gen-Probe, Incorporated

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The objective of this multi-center clinical study is to determine the association of the PCA3 Score with prostate biopsy outcome and validate the assay's performance characteristics in men with previous negative prostate biopsies. An elevated PCA3 Score is thought to be associated with an increased likelihood of positive biopsy. The results of this study are intended to be used for regulatory filings for use as an in vitro diagnostic test.

Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Other: PCA3 Assay Not Applicable

Detailed Description:
PCA3 is a gene that is highly over-expressed in more than 90% of prostate cancers, and that can be quantified in urine specimens following a digital rectal examination. Studies have shown that because PCA3 is highly specific for prostate cancer, it predicts the results of repeat biopsies more accurately than traditional prostate-specific antigen (PSA) testing. Gen-Probe's PROGENSA(R) PCA3 assay is the first urine-based molecular diagnostic assay for prostate cancer.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 507 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Clinical Evaluation of the PROGENSA(R) PCA3 Assay in Men With a Previous Negative Biopsy Result
Study Start Date : August 2009
Actual Primary Completion Date : April 2010
Actual Study Completion Date : April 2010

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: PCA3 Assay Other: PCA3 Assay
Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Association of PCA3 Score With Prostate Biopsy Outcome (PCA3 Score Using Cutoff of 25.) [ Time Frame: At the time of biopsy ]
    The likelihood of positive biopsy was determined by the PCA3 Score expressed as a binary categorical variable: PCA3 Score >=25 was positive, PCA3 Score <25 was negative


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men 40+ years of age who have had at least 1 previous negative prostate biopsy, who have never had a positive prostate biopsy, and who have been recommended for a repeat biopsy by their clinician.
  • The subject must be able to comprehend and sign an approved informed consent form and other applicable study enrollment documents

Exclusion Criteria:

  • Use of medications or hormones that are known to affect serum PSA levels within 3 - 6 months of study enrollment
  • Clinical symptoms of urinary tract infection (including prostatitis) at the time of enrollment
  • History of prostate cancer
  • History of invasive treatments for benign prostatic hypertrophy (BPH) or lower urinary tract symptoms within 6 months of study enrollment
  • Medical history or concurrent illness that the investigator considers sufficiently serious to interfere with the conduct, completion, or results of this trial, or constitutes an unacceptable risk to the subject
  • Participation in pharmaceutical or treatment related clinical study within 6 months of study enrollment. Exception: Trials for non-prostate conditions may be acceptable, with approval by the investigator and Sponsor
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01024959


Locations
Layout table for location information
United States, California
HealthCare Partners Medical Group
Los Angeles, California, United States, 90015
San Diego Clinical Trials
San Diego, California, United States, 92120
United States, Florida
South Florida Medical Research
Aventura, Florida, United States, 33180
Specialists in Urology
Naples, Florida, United States, 34102
Florida Urology Specialists
Sarasota, Florida, United States, 34237
United States, Indiana
Metropolitan Urology, PSC
Jeffersonville, Indiana, United States, 47130
United States, Louisiana
Regional Urology Specialists, LLC
Shreveport, Louisiana, United States, 71106
United States, New York
AccuMed Research Associates
Garden City, New York, United States, 11530
United States, Ohio
TriState Urologic Services PSC Inc. dba The Urology Group
Cincinnati, Ohio, United States, 45212
Columbus Urology Research, LLC
Columbus, Ohio, United States, 43220
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Urology San Antonio Research
San Antonio, Texas, United States, 78229
United States, Virginia
Virginia Urology
Richmond, Virginia, United States, 23235
Sponsors and Collaborators
Gen-Probe, Incorporated
Investigators
Layout table for investigator information
Study Director: Jennifer Reid, PhD Gen-Probe, Incorporated
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Gen-Probe, Incorporated
ClinicalTrials.gov Identifier: NCT01024959    
Other Study ID Numbers: 2009PCA301
First Posted: December 3, 2009    Key Record Dates
Results First Posted: November 7, 2012
Last Update Posted: November 12, 2012
Last Verified: November 2012
Keywords provided by Gen-Probe, Incorporated:
Prostate Cancer
Prostate Biopsy
PCA3
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
 Neoplasms by Site
Neoplasms
Prostatic Diseases